论文部分内容阅读
[目的]探讨术后复发晚期胃癌患者Her-2/neu表达及与临床病理特征和预后的相关性。[方法]分别采用免疫组织化学法(IHC)及荧光原位杂交法(FISH)对108例术后复发晚期胃癌患者进行Her-2/neu表达的检测,分析其与患者的年龄、性别、Lauren分型、组织学分级及与预后的相关性。[结果]108例患者中,IHC法检测Her-2/neu阳性表达13例,FISH法检测Her-2/neu阳性表达14例,两种方法均为阳性表达者10例,一致率为61.5%。15例正常胃黏膜中未见阳性表达。Her-2/neu表达与患者的年龄、性别、肿瘤部位、组织学分级、TNM分期、浸润深度、有无脉管浸润无关(P>0.05),而与患者的Lauren分型、淋巴结转移有关(P<0.05)。Her-2/neu阳性患者的中位疾病进展时间(TTP)为22.4个月(95%CI:23.44~26.55),阴性患者的中位TTP为25.0个月(95%CI:17.02~27.77),两者差异无统计学意义(P=0.215)。[结论 ]Her-2/neu可能是胃癌预后不良的标志之一。
[Objective] To investigate the relationship between the expression of Her-2 / neu and clinicopathological features and prognosis in patients with advanced gastric cancer after surgery. [Methods] The expression of Her-2 / neu in 108 patients with advanced gastric cancer with postoperative recurrence was detected by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) respectively. The correlations were analyzed with age, sex, Lauren Typing, histological grade and prognosis. [Results] The positive expression of Her-2 / neu in IHC was 13 cases and the positive expression of Her-2 / neu in 14 cases was detected by IHC in 10 of 108 cases. The coincidence rate was 61.5% . No positive expression was found in 15 cases of normal gastric mucosa. The expression of Her-2 / neu was not associated with age, sex, tumor location, histological grade, TNM stage, depth of invasion, and vascular invasion (P> 0.05), but not with Lauren’s classification and lymph node metastasis P <0.05). The median time to progression (TTP) was 22.4 months (95% CI: 23.44-26.55) for Her-2 / neu positive patients and 25.0 months (95% CI 17.02 to 27.77) for negative patients, The difference was not statistically significant (P = 0.215). [Conclusion] Her-2 / neu may be one of the markers of poor prognosis of gastric cancer.